Intel reported a return to profitability in the second quarter, following two consecutive quarters of losses. The results got a boost from the PC segment of the business, which has been battered in recent quarters but is now showing signs of recovery. While the results topped analyst expectations, revenue was still 15% lower than it was from a year ago. Yahoo Finance Live breaks down the numbers.
Intel stock rises on earnings beat, slow recovery in PC segment
07/28/2023 21:06
Intel reported a return to profitability in the second quarter, following two consecutive quarters of losses. The results got a boost from the PC segment of the business, which has been battered in recent quarters but is now showing signs of recovery. While the results topped analyst expectations, revenue was still 15% lower than it was from a year ago. Yahoo Finance Live breaks down the numbers.
TipRanks
Goldman Sachs Predicts up to 120% Rally for These 2 Stocks — Here’s Why They Have Solid Upside
It’s no secret that the big gains in the stock market this year have been on account of only a select number of equities surging ahead – namely, the Mega Caps, and mostly ones with AI exposure. While that has raised concerns among market watchers that the rally is not really as strong as it appears and masks a more fragile market, Sharmin Mossavar-Rahmani, head of the investment strategy group at Goldman Sachs, disagrees with such a prognosis. In fact, Mossavar-Rahmani thinks that if history is
TipRanks
Down More Than 40%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound
Reverse psychology can be considered a desired quality in the stock market. It is only natural to gravitate toward the leaders in any field, and an investor’s urge to hop on the latest surging stock in search of those sweet gains is understandable. However, anyone familiar with the ins and outs of investing will repeatedly say that overused mantra: ‘buy low, sell high.’ In recognizing that low price, investors can turn to Wall Street’s pros for help. The analysts have been busy lately, picking o
Investor's Business Daily
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals
Biogen announced Friday it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion, boosting the biopharmaceutical company's drug offerings for serious neurological diseases. Reata stock surged early as Biogen stock slid Friday. RETA stock skyrocketed nearly 52% early Friday during morning trades after Biogen reported it plans to pay $172.50 per share in cash for Reata.
Barrons.com
These Stocks Are Moving the Most Today: Intel, Ford, Exxon, P&G, Reata, Roku, Enphase, and More
Intel reports a surprise second-quarter profit, Ford delays its electric-vehicle production goals, Exxon's adjusted earnings miss forecasts, Reata Pharmaceuticals is being purchased by Biogen, Roku posts a narrower-than-expected loss, and Enphase Energy's revenue forecast disappoints.